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Abstract
Fetal growth restriction (FGR) occurs in *8% of pregnancies and is a major cause of perinatal mortality and
morbidity. There is no effective treatment. FGR is characterized by reduced uterine blood flow (UBF). In
normal sheep pregnancies, local uterine artery (UtA) adenovirus (Ad)-mediated overexpression of vascular
endothelial growth factor (VEGF) increases UBF. Herein we evaluated Ad.VEGF therapy in the overnourished
adolescent ewe, an experimental paradigm in which reduced UBF from midgestation correlates with reduced
lamb birthweight near term. Singleton pregnancies were established using embryo transfer in adolescent ewes
subsequently offered a high intake (n= 45) or control intake (n = 12) of a complete diet to generate FGR or
normal fetoplacental growth, respectively. High-intake ewes were randomized midgestation to receive bilateral
UtA injections of 5· 1011 particles Ad.VEGF-A165 (n= 18), control vector Ad.LacZ (n = 14), or control saline
(n= 13). Fetal growth/well-being were evaluated using serial ultrasound. UBF was monitored using indwelling
flowprobes until necropsy at 0.9 gestation. Vasorelaxation, neovascularization within the perivascular adven-
titia, and placental mRNA expression of angiogenic factors/receptors were examined using organ bath analysis,
anti-vWF immunohistochemistry, and qRT-PCR, respectively. Ad.VEGF significantly increased ultrasono-
graphic fetal growth velocity at 3–4 weeks postinjection ( p = 0.016–0.047). At 0.9 gestation fewer fetuses were
markedly growth-restricted (birthweight >2SD below contemporaneous control-intake mean) after Ad.VEGF
therapy. There was also evidence of mitigated fetal brain sparing (lower biparietal diameter-to-abdominal
circumference and brain-to-liver weight ratios). No effects were observed on UBF or neovascularization;
however, Ad.VEGF-transduced vessels demonstrated strikingly enhanced vasorelaxation. Placental efficiency
(fetal-to-placental weight ratio) and FLT1/KDR mRNA expression were increased in the maternal but not fetal
placental compartments, suggesting downstream effects on placental function. Ad.VEGF gene therapy im-
proves fetal growth in a sheep model of FGR, although the precise mechanism of action remains unclear.
Introduction
Fetal growth restriction (FGR), which is defined asthe failure of a fetus to achieve its genetically pre-
determined growth potential, affects*8% of pregnancies in
developed countries (Mandruzzato et al., 2008). It is a leading
cause of perinatal mortality (Bernstein et al., 2000) and as-
sociated with considerable morbidity in neonatal and later
life (Barker, 2006; Halliday, 2009). FGR may complicate
genetic syndromes, chromosomal abnormalities, structural
anomalies, and congenital infections. In such cases the un-
derlying condition dictates the prognosis. However, >60%
of FGR occurs secondary to uteroplacental insufficiency
(Ghidini, 1996), which is characterized by reduced uterine
blood flow (UBF). Fetal growth in sheep is directly pro-
portional to UBF when experimentally restricted by vari-
able degrees of uterine artery (UtA) embolization (Lang
et al., 2003), and data from human FGR pregnancies indi-
cate that UBF is attenuated from midgestation (Konje et al.,
2003). There is no effective treatment for uteroplacental
FGR. Management constitutes fetal surveillance and de-
ciding when to deliver the baby, balancing the risks of
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iatrogenic prematurity versus the risks of hypoxic tissue
damage. Early delivery does not reduce perinatal mortality as,
while it prevents some stillbirths, it results in more neonatal
deaths (GRIT Study Group, 2003).
Attenuated UBF directly limits substrate delivery to the
developing fetus. Attempts to increase UBF using vasodila-
tors have been unsuccessful (Figueroa and Maulik, 2006), and
systemic delivery can even worsen uterine perfusion through
widespread maternal vasodilatation (Miller et al., 2009), an
effect known as the placental steal phenomenon. To over-
come this problem we have developed an approach to locally
target the uteroplacental circulation using adenoviruses (Ad)
encoding vascular endothelial growth factor (VEGF). VEGF
is an important biological agent that induces vasodilatation,
angiogenesis, and vascular protection (Holmes and Zachary,
2005). Previous work in normal midgestation sheep preg-
nancies demonstrated a significant increase in UBF after UtA
injection of Ad.VEGF-A165, which was sustained for up to 4
weeks (Mehta et al., 2011). Ad.VEGF-A165 upregulated en-
dothelial nitric oxide synthase (eNOS) expression in the UtA,
and Ad.VEGF-A165-treated vessels demonstrated an en-
hanced vasodilator response to bradykinin and neovascular-
ization within the perivascular adventitia (David et al., 2008).
Herein we tested the hypothesis that an Ad.VEGF-
mediated increase in UBF would improve fetal growth in
pregnancies complicated by FGR. We used the overnourished
adolescent sheep model of FGR because it is characterized by
a major reduction in UBF by midgestation and replicates
many key features of uteroplacental human FGR without any
need for surgical interference (Wallace et al., 2008). Over-
nourishing pregnant adolescent ewes by offering a high-
intake diet throughout gestation paradoxically results in major
placental and FGR relative to pregnancies of control-fed
adolescent ewes (Wallace et al., 2006a). Overnourishing the
young adolescent, who is still growing during pregnancy,
results in accelerated maternal tissue deposition with nutrient
partitioning away from the gravid uterus at the expense of
the fetus. FGR is accompanied by impaired placental vascu-
larization and secretory function and reduced placental ex-
pression of VEGF and fms-related tyrosine kinase 1 (FLT1)
(Redmer et al., 2005, 2009; Lea et al., 2007). In common with
human FGR, asymmetrical growth restriction with preserva-
tion of brain growth (brain sparing) and increased umbilical
artery (UA) Doppler indices are apparent (Wallace et al., 2000;
Carr et al., 2012). A variable response to nutritional manipu-
lation is observed, resulting in a wide range of fetal and pla-
cental growth trajectories. Overall *52% of pregnancies in
overnourished adolescents result in ‘‘marked’’ FGR (with a
birthweight more than 2 standard deviations [SDs] below the
mean birthweight of normal control fetuses) with an *48%
reduction in placental and fetal weights (Wallace et al., 2004).
The goal herein was to establish proof of principle for the
efficacy and safety of Ad.VEGF on fetal growth in a large
animal model of FGR. Thus, our primary aim was to de-
termine the effects of midgestation Ad.VEGF UtA injection
on UBF, fetal growth velocity, fetal weight in late gestation,
proportions of fetuses demonstrating marked FGR, and fetal
body composition, organ weights, and gross morphology. A
secondary aim was to investigate potential mechanisms of
action by assessing vascular relaxation, neovascularization
within the perivascular adventitia, and placental mRNA
expression of selected angiogenic factors and receptors.
Materials and Methods
Experimental animals
Animal procedures were approved by the UK Home Office
under the Animals (Scientific Procedures) Act 1986 and by
local ethics committee review. Ewes were housed in indi-
vidual pens under natural lighting conditions at the Rowett
Institute of Nutrition and Health (57N, 2W). Embryos were
derived from superovulated donor ewes (Scottish Black-
face·Border Leicester) inseminated by a single sire (Dorset
Horn) to establish exclusively singleton pregnancies and
maximize genetic homogeneity, as described (Wallace et al.,
1997). After embryo transfer, the adolescent recipients
(Dorset Horn·Mule) were allocated to one of two nutritional
treatments: a control intake (C) to promote normal fetopla-
cental growth (n=12), or a high intake (H) of the same com-
plete diet (*2 ·C) to generate FGR (n = 45), as described
(Wallace et al., 2006b).
Ultrasound
At 83– 0.1 days gestation ewes underwent detailed ultra-
sound examination including baseline measurements of the
fetal abdominal circumference (AC) and biparietal diameter
(BPD), and placentome index, as described (Carr et al., 2011).
In addition, the deepest vertical pool of amniotic fluid was
quantified and a free loop of umbilical cord examined using
pulsed wave Doppler ultrasound. Three consecutive UA
Doppler waveforms were manually traced, from which the
pulsatility index (PI) was determined. UA PI is an indicator of
fetoplacental vascular resistance, which relates to fetal well-
being, and is the primary surveillance tool in human preg-
nancies complicated by FGR. Between 98– 0.1 and 126– 0.3
days of gestation, scans were repeated weekly to assess fetal
growth/well-being. All scans were performed by a single
operator accredited in advanced obstetric ultrasound (D.J.C.)
blind to the treatment allocation using a Logiq 400 CL ma-
chine (GE, Milwaukee, WI) with a 5.0MHz curvilinear probe.
Gene therapy
At 89– 0.2 days of gestation ewes underwent a midline
laparotomy. Anesthesia was induced with 5mg/kg intravenous
propofol and maintained by inhaled isoflurane. An ultrasonic
perivascular flow probe (PSS Series, size 4 or 6mm; Transonic
Systems Inc., Ithaca, NY) was fitted around the main trunk of
the UtA supplying the gravid uterine horn. Subsequently, the
main trunk of each UtA was occluded and injected with first-
generation replication (E1, E3-deleted)-deficient Ads (5· 1011
particles in 10ml normal saline; titer determined at OD260)
containing the VEGF-A165 gene (Ad.VEGF) or the b-galacto-
sidase gene (Ad.LacZ), as described (David et al., 2008). High-
intake ewes were randomized to receive Ad.VEGF (H+
Ad.VEGF, n= 18), Ad.LacZ (H+Ad.LacZ, n=14), or saline
only (H+Saline, n=13). Control-intake ewes all received saline
(C+Saline, n=12). Between 92– 0.2 and 130–0.2 days of
gestation, UBF was measured continuously for 45min on al-
ternate days telemetrically, as described (Mehta et al., 2011).
Necropsy
At 131– 0.2 days of gestation, ewes and fetuses were
euthanized. Necropsy was performed at this stage to strike a
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balance between allowing sufficient time postinjection to
adequately assess the potential impact on fetal growth (a
gradual process) while intervening before the onset of labor,
which can occur from as early as 135 days gestation in
overnourished adolescent dams (Wallace et al., 2006a).
Fetuses were dried, weighed, and dissected. Umbilical girth,
biparietal head diameter, and lengths of the tibial and
femoral bones were measured with callipers. All major inter-
nal organs were macroscopically examined and weighed. The
uterine arterial tree was carefully dissected and segments were
obtained from both gravid and nongravid horns at three levels
of branching: main trunk of the UtA (designated UtA1), first
branches (UtA2), and second branches (UtA3). Duplicate seg-
ments of UtA1–3 were immersion-fixed in neutral buffered
formalin saline, processed through an ethanol gradient, and
paraffin-embedded for subsequent immunohistochemistry. In a
subset of 22 animals (n=4, 7, 5, and 6 from C+Saline, H+
Ad.VEGF, H+Saline, and H+Ad.LacZ groups, respectively),
additional segments of UtA2–3 were obtained and stored over-
night in cold Krebs Ringer buffer pending organ bath analysis.
Finally, whole placentomes, comprising both fetal (cotyledon-
ary) and maternal (caruncular) tissues, were counted and
weighed. Four representative placentomes were separated into
cotyledonary/caruncular components by gentle traction, snap-
frozen in isopentane chilled with liquid nitrogen, and stored at
- 80C pending RNA extraction. Total placental weight was
calculated (total placentome weight+membrane weight).
Laboratory analyses
To assess vascular contraction and relaxation, segments
of UtA2/UtA3 from 22 pregnancies were cut into 2–3mm
ring segments and subjected to increasing doses of phenyl-
ephrine and bradykinin in an organ bath, as described
(David et al., 2008). To assess neovascularization, sections
of UtA1–3 from all animals were immunostained with the
endothelial cell marker anti–von Willebrand factor (1:200),
as described (Mehta et al. 2011). Slides were examined
at · 20 magnification to identify the perivascular adventitia.
All positively stained structures with a distinct lumen within
this layer were counted. The adventitial area was determined by
image analysis (Motic Images 2.0;MoticChinaGroupCo.Ltd.,
Indusxiamen, China). The number of perivascular adventitial
blood vessels was examined in absolute terms and per unit
adventitial area. Finally, RNA was extracted from separately
snap-frozen caruncular/cotyledonary tissues and quantitative
real-time reverse transcription polymerase chain reaction used
to determine mRNA expression of nine angiogenic factors/
receptors using ovine-specific probes/primers, as described
(Redmer et al., 2005): VEGF, VEGF receptors 1 (FLT1) and 2
(KDR), nitric oxide synthase (NOS3), fibroblast growth factor 2
(FGF2), angiopoietin 1 (ANG1), angiopoietin 2 (ANG2), endo-
thelial tyrosine kinase (TEK), and nitric oxide receptor soluble
guanylate cyclase (SGC). Individual mRNA for each gene of
interest was quantified relative to each sample’s internal 18S
RNA content. For all laboratory analyses the individual in-
vestigator was blinded to the treatment group by means of
block and sample coding until analysis was complete.
Statistical analyses
During study design a power calculation was performed
based on preliminary data showing a 40% increase in UBF
after Ad.VEGF delivery in normal sheep pregnancy (David
et al., 2008) and prior evaluation of UBF in the overnourished
adolescent model (Wallace et al., 2008). Assuming inter-
animal variability of 143ml/min, it was estimated that 11
animals per group would be required to detect a 50% increase
in UBF (212ml/min) with 90% power. Study results were
analyzed using the Statistical Package for the Social Sciences
(SPSS) version 19.0 (SPSS Inc., Chicago, IL). After con-
firming normality using Q:Q plots, comparisons were made
across the four groups using one-way analysis of variance
(ANOVA) and post hoc test of least significant differ-
ence (LSD). As there were no significant differences between
the two different high-intake control groups (H+Ad.LacZ
and H + Saline) for any of the parameters studied, these
groups were combined as a single group (H +Ad.LacZ/
Saline, n = 27) for further comparisons, also by ANOVA
and post hoc test of LSD. Categorical data were compared
using Fisher’s exact test. Fetal weight was analyzed in
absolute terms (ANOVA) but was additionally analyzed
using a categorical approach by determining the numbers
of fetuses exhibiting ‘‘marked’’ FGR within each group.
An accepted definition of marked FGR is a birthweight that
falls > 2SD below the genetic potential (Robinson et al.,
1979). In this paradigm the latter can be estimated from the
contemporaneous control-intake group on a study-by-study
basis. The use of embryo transfer and randomization to nu-
tritional treatment on the basis of embryo donor source plus
use of a single sire (see above) all helped maximize genetic
homogeneity when deriving the singleton pregnancies herein.
For the UtA analyses, general linear model was used to assess
differences between study groups while taking into account
the level of branching (UtA1–3) and uterine horn (gravid/
nongravid). All data are presented as mean– standard error of
the mean (SEM) unless otherwise stated.
Results
There were no adverse maternal or fetal complications
during the surgery or the postoperative recovery period. In
particular, there were no adverse fetal responses to the 5min
UtA occlusion. All pregnancies remained viable until the
point of necropsy at 131– 0.2 days of gestation and no
maternal health problems were observed.
Fetoplacental growth and fetal well-being
Figure 1A shows serial fetal AC measurements from
98– 0.1 until 126– 0.3 days of gestation. As expected, fetuses
of control-intake ewes grew normally and hence had greater
AC measurements compared with the compromised fetuses of
high-intake ewes from 105– 0.1 days of gestation onward
( p< 0.001). Compared with equivalent presurgery baseline
values, AC measurements increased more in H+Ad.VEGF
versus H+Saline/H+Ad.LacZ groups and were greater at
112– 0.1 (241– 2.8 vs. 233– 2.3 and 233– 2.5mm, p= 0.031
and p= 0.047, respectively) and 119– 1 days of gestation
(258– 3.1 vs. 249– 2.3 and 248– 2.8mm, p= 0.032 and
p= 0.016, respectively), corresponding to 22– 0.2 and 29– 0.2
days postinjection. No treatment differences were evident
between high-intake groups at 126 – 0.3 days of gestation,
when AC measurements were more variable. BPD mea-
surements were not different between any groups at any
gestational age. Consequently, differences in BPD:AC ratio
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(an index of fetal brain sparing) were apparent (Fig. 1B).
With advancing gestation, BPD:AC ratios diminished pro-
gressively in all groups but were lower in C + Saline versus
H + Saline and H +Ad.LacZ groups ( p < 0.001) from
105 – 0.1 days of gestation onward. BPD:AC ratios within
the H +Ad.VEGF group fell faster relative to H + Saline and
H +Ad.LacZ and were lower from 112 – 0.1 days of gesta-
tion onward ( p < 0.001–0.016). By 126 – 0.1 days of ges-
tation they were similar to the C + Saline group ( p = 0.807),
indicating that fetal brain sparing had been ameliorated by
Ad.VEGF treatment.
Figure 1C shows serial measurements of UA PI throughout
the study period. UA PI values fell with advancing gestation
and were lower in C+Saline relative to all three high-intake
groups from 98– 0.1 days of gestation onward ( p< 0.001–
0.038). There were no differences between H+Ad.VEGF and
H+Saline or H+Ad.LacZ groups. There were no differences
between groups in amniotic fluid measurements (data not
shown). Finally, serial measurements of the placentome index
are shown in Fig. 1D. The placentome index was greater in
C + Saline versus high-intake groups at all time points
( p < 0.001–0.005) and also decreased with advancing ges-
tation. There were no differences in this two-dimensional
ultrasound measure of placental size between the three high-
intake groups.
Fetal weight and body composition
Table 1 shows fetal and placental weights, fetal anthro-
pometric data, and major organ weights at necropsy at
131 – 0.2 days of gestation. Fetal weight was reduced in all
three high-intake groups relative to the normally grown
controls (minimum p = 0.001 for individual comparisons).
When comparing the group means, fetal weight in the H+
Ad.VEGF group was not significantly different from that of
the H+Saline or H+Ad.LacZ groups in late gestation
( p= 0.375 and p= 0.149, respectively). However, significant
differences were observed in the numbers of fetuses ex-
hibiting ‘‘marked’’ FGR (birthweight > 2SD below the non-
FGR control mean). The mean–SD within the C+Saline
group was 5084– 431 g, giving a minus 2SD cutoff of 4222 g.
Figure 2 illustrates the proportion of fetuses in the H +
FIG. 1. Ultrasound assessment of fetoplacental growth and umbilical blood flow. Serial ultrasound measurements of fetal
AC (A), biparietal head diameter:AC ratio (B), umbilical artery pulsatility index (C), and placentome index (D) between
83 – 0.1 and 126 – 0.3 days of gestation in singleton-bearing adolescent ewes fed a control (C; open squares, n = 12) or a
high (H) dietary intake to generate normal and compromised fetoplacental growth, respectively. After baseline measure-
ments at 83 – 0.1 days of gestation, ewes received bilateral uterine artery injections of Ad.VEGF (closed circles, n = 18),
Ad.LacZ (open triangles, n = 14), or saline (open diamonds for H + Saline, n= 13, open squares for C+ Saline, n = 12) at
89 – 0.2 days of gestation (indicated by arrow). Asterisks denote gestational time points at which there were significant
differences in H+Ad.VEGF relative to H + Saline and H +Ad.LacZ groups ( p < 0.05 for post hoc comparisons). AC,
abdominal circumference; Ad, adenovirus; LacZ, b-galactosidase; VEGF, vascular endothelial growth factor.
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Ad.VEGF and H +Ad.LacZ/Saline (combined) groups
weighing less than or greater than 4222 g (marked FGR and
non-FGR, respectively). Significantly fewer fetuses were
categorized as markedly FGR in H +Ad.VEGF compared
with H+Ad.LacZ/Saline groups.
Placentome weight and total placental weight were both
reduced in control- versus high-intake pregnancies ( p< 0.001)
but were not significantly different between H+Ad.VEGF,
H+Saline, and H+Ad.LacZ groups. The fetal-to-placental
weight ratio (an index of placental efficiency) was highest in
the H+Ad.VEGF group, and greater than normally grown
control-intake pregnancies ( p = 0.009). Physical measure-
ments of the fetus at necropsy, namely, biparietal head di-
ameter, umbilical girth, and long bone lengths, were in
agreement with the equivalent ultrasonographic fetal bi-
ometry at 126 – 0.3 days of gestation (r = 0.641–0.745,
p < 0.001, n = 57). Postmortem measurements of umbilical
girth and femoral length were reduced in all three high-
intake groups relative to fetuses of control-intake ewes
( p = 0.001–0.044), while biparietal head diameters were
significantly reduced only in H+Saline and H+Ad.LacZ
versus C+Saline groups ( p= 0.013/p= 0.015), H+Ad.VEGF
being intermediate. The apparent differences between study
groups in absoluteweights of liver, kidneys, perirenal fat depots,
heart, lungs, and thyroid (Table 1) were no longer significant
when expressed per kg fetus (data not shown), indicating a
proportionate shift in these indices of fetal size across all high-
intake groups. By contrast, despite no differences between
groups in absolute brain weight, both relative brain weight and
brain:liver weight ratios were increased in H+Ad.LacZ/Saline









(n = 14) p
Fetal weight (g) 5084– 124a 4395– 188b 4153– 202b 4008 – 234b 0.003
Placentome weight (g) 521– 82.5a 366 – 96.6b 372– 106.7b 345 – 93.6b < 0.001
Placentome number 71.0 – 0.78a 68.6 – 1.28ab 66.6– 1.12b 66.8 – 1.00b 0.043
Total placental weight (g) 802– 36.1a 594 – 33.5b 595– 42.4b 570 – 37.2b < 0.001
Fetal to placental weight ratio 6.45 – 0.266a 7.52 – 0.250b 7.16– 0.254ab 7.21 – 0.339ab 0.018
Biparietal head diameter (mm) 71.0 – 0.78a 68.6 – 1.28ab 66.6– 1.12b 66.8 – 1.00b 0.043
Umbilical girth (mm) 363– 4.9a 340 – 6.2b 336– 7.2b 328 – 7.0b 0.006
Length of femoral bone (mm) 89.8 – 1.00a 85.9 – 1.42b 84.4– 1.11b 83.9 – 1.56b 0.024
Length of tibial bone (mm) 107– 1.2a 102 – 1.9ab 101– 1.4b 100 – 1.9b 0.070
Brain weight (g) 47.0 – 0.95 44.1 – 1.58 44.8– 0.79 44.5 – 1.10 0.431
Paired adrenal weight (g) 0.50 – 0.023 0.46 – 0.022 0.47– 0.027 0.50 – 0.032 0.666
Pancreas weight (g) 3.93 – 0.134 3.75 – 0.197 3.63– 0.287 3.51 – 0.182 0.582
Stomach weight (g) 32.6 – 1.46 30.2 – 1.21 30.6– 0.85 28.5 – 1.26 0.171
Small intestine weight (g) 51.2 – 2.70 44.7 – 2.33 48.1– 2.45 42.9 – 2.11 0.109
Large intestine weight (g) 14.5 – 1.09 12.9 – 0.49 13.3– 0.59 12.4 – 0.75 0.190
Liver weight (g) 161– 7.0a 134 – 6.3b 132– 7.8b 121 – 9.3b 0.007
Spleen weight (g) 9.03 – 0.415 8.10 – 0.444 8.16– 0.736 7.57 – 0.598 0.374
Paired kidney weight (g) 27.5 – 0.77a 25.1 – 1.17ab 23.4– 1.14b 22.0 – 1.43b 0.019
Perirenal fat weight (g) 21.1 – 0.58a 18.2 – 0.93b 18.9– 1.05ab 17.2 – 1.09b 0.055
Heart weight (g) 36.7 – 1.20a 33.6 – 1.48ab 30.9– 1.29b 29.6 – 1.45b 0.007
Lung weight (g) 172– 10.9a 158 – 8.5ab 142– 8.7b 128 – 10.8b 0.021
Thymus weight (g) 7.15 – 0.447 6.72 – 0.489 5.95– 0.581 6.10 – 0.661 0.432
Thyroid weight (g) 0.97 – 0.021a 0.77 – 0.069b 0.80– 0.044b 0.74 – 0.048b 0.025
Carcass weight (g) 3289– 92.2a 2847– 134.7b 2779– 132.6b 2669 – 157.7b 0.021
Ad, adenovirus; ANOVA, analysis of variance; LacZ, b-galactosidase; SEM, standard error of the mean; VEGF, vascular endothelial
growth factor.
All data are presented as mean – SEM. p-Values reported in table are for overall ANOVA. Mean values within a row with unlike
superscripts are significantly different ( p£ 0.05 for individual comparisons). Individual post hoc comparisons are detailed in the text.
FIG. 2. Incidence of marked FGR. Number of fetuses de-
livered by hysterotomy at 131– 0.2 days gestation from sin-
gleton-bearing adolescent ewes fed a high (H) dietary intake
(to compromise fetoplacental growth) with marked FGR
(closed bars) or mild FGR (open bars). Marked FGR was
defined as a birthweight > 2SD below the mean birthweight
of the fetuses of 12 contemporaneous control-intake ewes that
demonstrating normal fetoplacental growth (< 4222g for the
present study). Fetuses with birthweights > 4222g were of
similar weight to normally grown controls and therefore
termed ‘‘non-FGR.’’ In midgestation H ewes received bilat-
eral uterine artery injections of Ad.VEGF or control treatment
(Ad.LacZ/Saline). Proportions were compared using Fisher’s
exact test. FGR, fetal growth restriction.
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groups combined compared with the C+Saline group, com-
mensurate with fetal brain sparing (11.2– 0.30 vs. 9.3– 0.24 g/
kg, p< 0.001; and 0.37– 0.02 vs. 0.30– 0.01, p= 0.001, re-
spectively). Importantly, both indices of fetal brain spar-
ing were lower after Ad.VEGF treatment (10.1– 0.26 g/kg,
p= 0.009; and 0.33– 0.01, p= 0.046, respectively). Gross or-
gan morphology was normal in all cases.
Uterine blood flow
Serial measurements of UBF via the main trunk of the UtA
supplying the gravid horn between 92– 0.2 and 130– 0.2 days
of gestation are shown in the Fig. 3. Mean UBF was greater in
C+Saline versus H+Saline/H+Ad.LacZ groups at 94– 0.1
and 96 – 0.1 days of gestation ( p = 0.006–0.042) but not
thereafter. UBF measurements in the H+Ad.VEGF group
were not significantly different when compared with any other
group at any point. The gestational increase in UBF over the
study period was not different between C+Saline, H+
Ad.VEGF, H+Saline, and H+Ad.LacZ groups in absolute
(134– 96.3, 188– 100.6, 201– 115.1, and 176– 78.6ml/min,
respectively, p = 0.531) or relative terms (41.0 – 9.72%,
61.1 – 7.68%, 76.7 – 19.02%, and 65.4– 9.42%, respectively,
p = 0.248). There were no differences in average UBF be-
tween groups ( p = 0.357 and p = 0.565, respectively).
Vascular reactivity
Figure 4A shows the contractile response of UtA2/UtA3
vessel segments to increasing concentrations of phenyleph-
rine in the organ bath when examined on the day after
necropsy. Satisfactory dose–response curves were achieved
in 76 of 78 vessels examined from a subset of 22 animals.
For these vessels the degree of contraction was somewhat
greater in H+Ad.VEGF relative to H+Ad.LacZ/Saline groups
at phenylephrine concentrations of -6.0 log M upward
( p£0.001–0.04) and was not different to the C+Saline group
at any point. The maximum contractile response (EmaxC) was
also increased in H+Ad.VEGF versus H+Ad.LacZ/Saline
groups (190 – 18.5 vs. 148 – 3.2%, p = 0.04) and was not
significantly different from that of the C + Saline group
( p = 0.718).
Figure 4B illustrates the subsequent relaxation response to
bradykinin after precontraction with a suboptimal dose of
phenylephrine (1lM) that caused a contraction equivalent to
50–60%of EmaxC. The response to bradykininwas insufficient
for analysis in 3 of 14 vessel segments (27.3%) in C+Saline, 7
of 24 (29.2%) in H+Ad.VEGF, 7 of 18 (38.9%) in H+Saline,
and 6 of 20 (30.0%) in H+Ad.LacZ groups, which meant that
no data from these vessels were available for analysis. For the
remaining vessels, vasorelaxation was markedly greater in
H+Ad.VEGF compared with all other groups ( p£ 0.001–
0.015) at concentrations of - 8.5 logM upward. Themaximum
relaxation (EmaxR) was higher in H+Ad.VEGF (75– 6.2%)
relative to both H+Ad.LacZ/Saline (41– 6.1%, p£ 0.001) and
C+Saline (30– 6.0%, p£ 0.001) groups. There were no sig-
nificant differences in any indices of vascular relaxation be-
tween branches UtA2 and UtA3 ( p= 0.655) or between those
from the gravid versus nongravid horns ( p= 0.562) and no
interactions between these factors and treatment group
( p= 0.129–0.778).
Neovascularization
Supplementary Table S1 (Supplementary Data are avail-
able online at www.liebertpub.com/hum) shows absolute
numbers of blood vessels in the perivascular adventitia,
adventitial area, and vessel density (number of vessels per
unit adventitial area) stratified by UtA branch. Both vessel
number and adventitial area decreased with successive
branching ( p£ 0.001), and consequently there were no dif-
ferences in vessel density between branches UtA1, 2, and 3
( p= 0.113). There were also no differences between vessels
harvested from the gravid and nongravid horns. Although
there were no differences in absolute vessel number between
study groups per individual branch, overall there were more
vessels per section in H+Ad.VEGF and H+Ad.LacZ/Saline
versus C+Saline groups (142– 7.2 and 138– 11.0 vs. 105–
7.0, p= 0.006 and p= 0.024, respectively) without any sig-
nificant differences in adventitial area by group ( p= 0.846).
Consequently, vessel density was significantly increased in
high-intake relative to control-intake pregnancies, both across
and within different branches ( p£ 0.001). There was no de-
monstrable effect of Ad.VEGF.
Placental analyses
Table 2 shows the mRNA expression of nine angiogenic
factors/receptors evaluated separately in the maternal and fetal
placental compartments. In caruncular tissues, mRNA ex-
pression of endogenous VEGF and its two main receptors
(FLT1 and KDR) was reduced in H+Ad.LacZ/Saline relative
to C+Saline groups ( p= 0.012, p= 0.031, and p= 0.039, re-
spectively). Although endogenous VEGF expression was not
significantly influenced by Ad.VEGF treatment, expression
FIG. 3. In vivo assessment of uterine blood flow. Serial
measurements of UBF were recorded between 92 – 0.2 and
130 – 0.2 days of gestation using an ultrasonic perivascular
flow probe placed around the main trunk of the UtA sup-
plying the gravid horn in singleton-bearing adolescent ewes
fed a control (C; open squares, n= 12) or a high (H) dietary
intake to generate normal and compromised fetal and pla-
cental growth trajectories, respectively. UBF determinations
were commenced 3 days after bilateral UtA injections of
Ad.VEGF (closed circles, n= 18), Ad.LacZ (open triangles,
n = 14), or saline (open diamonds for H+ Saline, n= 13, and
open squares for C + Saline, n = 12). Asterisks denote ges-
tational time points at which there were significant differ-
ences between the four groups (overall ANOVA p < 0.05).
UBF, uterine blood flow; UtA, uterine artery.
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of both FLT1 and KDR was increased in H+Ad.VEGF
versus H+Ad.LacZ/Saline groups ( p= 0.028 and p= 0.034,
respectively) and was similar in magnitude to control-intake
pregnancies. In cotyledonary tissues, mRNA expression of
ANG2 and TEK was significantly increased in both H +
Ad.VEGF and H+Ad.LacZ/Saline compared with C+Saline
groups (ANG2: p= 0.032 and p= 0.003; TEK: p= 0.018 and
p= 0.045, respectively). There was no significant effect of
Ad.VEGF on expression of any genes in the fetal placental
compartment.
Discussion
The most important finding of this study is that Ad.VEGF
treatment midpregnancy improves prenatal growth velocity
in a well-characterized ovine paradigm of uteroplacental
FIG. 4. Uterine artery vascular reactivity. Dose–response curves to phenylephrine (A) and bradykinin (B), reflecting
vascular contraction and relaxation, respectively, for UtA segments (from gravid and nongravid horns at two levels of
branching) from 22 singleton-bearing adolescent ewes fed a control (C; open squares) or a high (H) dietary intake to
generate normal and compromised fetoplacental growth, respectively, and necropsied at 131– 0.2 days of gestation. At
89 – 0.2 days of gestation, H ewes received bilateral uterine artery injections of Ad.VEGF (closed circles) or Ad.LacZ/
Saline (open circles). Asterisks indicate concentrations of bradykinin at which there were significant differences in H+
Ad.VEGF versus H+Ad.LacZ/Saline and C + Saline groups ( p < 0.05 for overall ANOVA and post hoc comparisons).
Table 2. Placental Expression of Angiogenic Factors/Receptors
Placental compartment






(n = 27) p
Maternal caruncle
VEGF 27.3 – 3.04a 23.7 – 1.75ab 20.3– 1.26b 0.036
FLT1 18.8 – 2.26a 18.1 – 2.36a 12.5– 1.36b 0.031
KDR 23.8 – 2.40a 23.2 – 2.52a 17.4– 1.43b 0.040
NOS3 28.6 – 2.82 37.6 – 3.25 33.5– 2.65 0.185
FGF2 15.7 – 1.54 13.8 – 1.28 12.5– 1.15 0.280
ANG1 24.0 – 1.622 21.1 – 1.65 20.1– 1.48 0.291
ANG2 14.0 – 1.17 14.7 – 0.85 12.4– 0.69 0.110
TEK 21.6 – 2.63 22.9 – 1.51 19.8– 1.33 0.370
SGC 16.5 – 1.52 16.2 – 1.15 13.6– 0.96 0.138
Fetal cotyledon
VEGF 26.5 – 3.53 30.6 – 2.67 30.9– 2.59 0.579
FLT1 15.1 – 2.42 13.0 – 1.50 14.6– 1.44 0.699
KDR 17.0 – 2.44 17.6 – 1.59 18.4– 1.80 0.877
NOS3 16.1 – 2.17 21.5 – 3.01 19.6– 1.87 0.383
FGF2 9.9 – 1.07 10.6 – 0.58 11.3– 0.69 0.430
ANG1 21.9 – 1.64 20.9 – 0.94 23.1– 0.90 0.312
ANG2 13.0 – 0.79a 16.0 – 0.73b 16.9– 0.80b 0.010
TEK 14.0 – 0.79a 16.8 – 0.71b 16.2– 0.61b 0.049
SGC 8.9 – 0.90 9.3 – 0.81 8.3 – 0.40 0.517
ANG1, angiopoietin 1; ANG2, angiopoietin 2; FGF2, fibroblast growth factor 2; FLT1, fms-related tyrosine kinase 1 (VEGF receptor 1);
KDR, kinase insert domain receptor (VEGF receptor 2); NOS3, nitric oxide synthase; SGC, soluble guanylate cyclase (nitric oxide
receptor); TEK, endothelial tyrosine kinase; VEGF, vascular endothelial growth factor.
p-Values shown are for overall ANOVA. Mean values within a row with unlike superscripts are significantly different ( p < 0.05 for
individual post hoc comparisons). All data are presented as mean – SEM.
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FGR. This is apparent from the greater AC measurements 3
and 4 weeks after Ad.VEGF treatment compared with in-
active treatments controlling for surgical intervention –
adenoviral infection in the putatively FGR pregnancies. The
AC is the most sensitive ultrasound marker of longitudinal
fetal growth in human and sheep pregnancy and correlates
strongly with birthweight (Degani, 2001; Nahum and Sta-
nislaw, 2003; Carr et al., 2011). Fetal growth was by no
means completely normalized, given that the growth tra-
jectories of Ad.VEGF-treated growth-restricted fetuses re-
mained significantly below those of the normally growing
fetuses of the contemporaneous control-fed ewes. However,
from a clinical perspective, it is not necessary to normalize
fetal growth in order to produce benefit. Very modest in-
creases in fetal growth, enough to delay delivery by a few
days or weeks, can greatly improve survival and morbidity
at the threshold of viability (Costeloe et al., 2000). In infants
born at 26 weeks of gestation, 1-year survival is 78% at
birthweights between 601 and 700 g compared with 51%
between 501 and 600 g (Morse et al., 2006), and survival at
6 years with only mild disability is 2.7 times higher (24% vs.
9%) at 25 weeks relative to 24 weeks of gestation (Marlow
et al., 2005).
Despite the improvement in fetal growth velocity observed
herein, fetal weight per se was not increased in Ad.VEGF-
treated versus Ad.Saline/LacZ-treated high-intake pregnancies.
This likely reflects the heterogeneous response to nutritional
manipulation, such that only half of overnourished adoles-
cent pregnancies result in marked FGR. It is revealing that
significantly fewer fetuses were categorized as markedly
growth-restricted at necropsy after Ad.VEGF treatment
and the incidence of marked FGR was notably less than
expected from historical data for overnourished adolescent
dams delivering spontaneously close to term (27.8% vs. 52%)
(Wallace et al., 2004).
Uteroplacental FGR is usually asymmetrical (Cox and
Marton, 2009). Faced with a reduced substrate supply, the
fetus prioritizes growth of important organs such as the
brain (Peebles, 2004). This ‘‘brain sparing’’ effect results in
higher ultrasound BPD:AC ratios and brain:liver weight
ratios. While this is generally regarded as an adaptive fetal
response to maintain cerebral perfusion, there is increasing
evidence that this phenomenon may confer an increased risk
of brain injury, as children born after FGR with antenatal
evidence of brain sparing have more cognitive and behav-
ioral problems (Scherjon et al., 2000; Roza et al., 2008;
Figueras et al., 2011). In this study there was significantly
less brain sparing in H +Ad.VEGF versus H +Ad.LacZ/
Saline groups, suggesting that Ad.VEGF treatment reduced
the need for such fetal adaptation.
Our original hypothesis was that increased fetal growth
would occur secondary to a therapeutic increase in UBF;
however, we demonstrated no effect of Ad.VEGF on UBF in
the growth-restricted pregnancies, despite obvious effects on
fetal growth and the incidence of marked FGR. However,
since we also failed to detect significant differences in UBF
between control- and high-intake pregnancies (other than for
a small difference in UBF at 94–96 days gestation) the lack
of a measurable effect of Ad.VEGF on UBF is perhaps
unsurprising. The failure to detect significant differences
between nutritional groups is in contrast with previous studies
in this paradigm in which UBF has been quantified using two
different methods. UBF measured using indwelling flow-
probes directly linked to a flowmeter (nontelemetrically) was
reduced by 42% in high-intake pregnancies at 88 days ges-
tation and by 30% (on average) over a subsequent 50-day
period (Wallace et al., 2008), while UBF measured by the
Fick principle in chronically instrumented sheep was reduced
by 36% at 130 days gestation in high-intake versus control-
intake pregnancies (Wallace et al., 2002). The reason for this
discrepancy in a key feature of our experimental paradigm is
unclear. Variability in initial UBF among the high-intake
ewes in the present study was *157ml/min, well below the
212ml/min derived from our original study using nontele-
metric equipment and used for the power calculation. It is
also noteworthy that the increase in flow from midgestation to
late gestation in normal pregnancies in the present study
(41%) was markedly lower than the 2-fold increase reported
previously over the same period in this model (Wallace et al.,
2008), as well as the 2.5–3.5-fold increase demonstrated by
earlier cross-sectional studies in sheep (Meschia, 1983) and
other mammals (Reynolds and Redmer, 1995; Reynolds
et al., 1986), and serially in humans (Konje et al., 2003). Both
aspects indicate with hindsight that the telemetric Physiogear
system was not functioning optimally and probably lacked
the required sensitivity and precision to detect both the ex-
pected differences between nutritional groups and the impact
of Ad.VEGF treatment. In addition, the assumption of a 50%
increase in UBF after Ad.VEGF treatment was based on a
previous study in normally developing pregnancies with a
very different experimental design, having compared effects
of Ad.VEGF injection into one UtA with Ad.LacZ injection
into the opposite UtA of the same animal (Mehta et al.,
2011). The increase in UBF was expressed as a percentage
change from baseline values within the same animal using
flow probes, which has been determined over 4–7 days before
gene therapy administration. By contrast, the present study
compared UBF between animals and in absolute terms.
In support of the hypothesis that VEGF treatment im-
proves fetal growth velocity in FGR by causing vascular
changes that increase blood flow, Ad.VEGF-transduced
vessels demonstrated significant differences in vascular re-
activity when examined in the organ bath, including an
enhanced contractile response to phenylephrine relative to
Ad.LacZ/Saline-treated vessels, which was similar in mag-
nitude to vessels harvested from control-intake pregnancies.
These results contrasted with our previous organ bath find-
ings in UtA branches from normal sheep pregnancies, which
demonstrated a reduced contractile response in Ad.VEGF-
transduced vessels at both short-term and long-term time
points: 4–7 days and 30–45 days posttreatment, respectively
(David et al., 2008; Mehta et al., 2011). Moreover, there was
a strikingly enhanced relaxation response to bradykinin rel-
ative to all other groups. We previously demonstrated in-
creased vasodilatation in the short-term only (David et al.,
2008) and hypothesized that the longer-term effects might be
mediated in part by adventitial neovascularization (Mehta
et al., 2011). In the present study we demonstrated no
significant effect of Ad.VEGF on angiogenesis. Notably,
however, there was increased neovascularization in all high-
intake groups relative to the control-intake group. This may
reflect an adaptive response aimed at optimizing UBF in
compromised pregnancies. Irrespective, on the background of
enhanced neovascularization secondary to high nutritional
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intakes, any further effect of Ad.VEGF delivery would be
more difficult to detect. The observation herein that Ad.
VEGF enhanced both vasoconstriction and vasorelaxation
may be explained by the fact that VEGF has vasoprotective
properties and can induce prolonged endothelial cell survival
(Zachary et al., 2000). The observation that Ad.VEGF-
transduced vessels were significantly more contractile than
Saline/Ad.LacZ-treated vessels from both control- and high-
intake animals may reflect improved overall vascular function
secondary to VEGF overexpression, with relative degradation
of the vessels (particularly the endothelium) in the absence of
Ad.VEGF transduction.
Alternatively, downstream placental effects may have
been responsible for mediating the beneficial effects of
Ad.VEGF on fetal growth. In this study we showed an up-
regulation of both VEGF receptors on the maternal side of
the placenta. The lack of significant changes on the fetal side
is in keeping with the absence of any effect on UA Doppler
indices herein, reflecting umbilical blood flow, and previous
observations that Ads do not cross the ovine placenta (Mehta
et al., 2011). Moreover, placental efficiency was also in-
creased after Ad.VEGF treatment.
This study provides the first proof of principle of Ad.
VEGF therapy to treat FGR, although the exact mechanism
remains far from clear. The main aim of this work was to
evaluate efficacy, and the long-term endpoint required (42
days after vector injection) unfortunately limited the extent
of any thorough mechanistic assessment, as it is known that
adenoviral expression is no longer detectable by 30 days
postinjection. Nevertheless, the relative strengths of our
study lie in the use of a well-characterized large-animal
FGR model, which replicates the key features of human
FGR secondary to uteroplacental insufficiency. However, no
animal model can completely represent the human condi-
tion. The main limitation of this work lies in the differences
between human (hemochorial) and ovine (syndesmochorial)
placentation, which lacks the trophoblastic invasion of the
spiral arteries that is considered essential for the maternal
adaptation to human pregnancy and underlies FGR and pre-
eclampsia. Furthermore, while this model features an early
insult on uteroplacental development, the resultant FGR is
relatively late-onset, equivalent to the third trimester of human
pregnancy. Evaluation of Ad.VEGF therapy in early-onset
FGR is needed. While there is clearly a long way to go with
respect to potential clinical translation, we have already se-
cured funding via the EU Framework Programme 7 to conduct
full reproductive toxicology studies, a bioethical study and a
phase I/IIa study in women with severe early-onset FGR, who
will be recruited around 22–26 weeks of gestation. The UtA in
such cases will be accessed via transfemoral catheterization
under X-ray guidance (an established interventional radio-
logical procedure) rather than via a laparotomy.
In summary, midgestation delivery of Ad.VEGF gene
therapy in FGR pregnancy induced by overnourishment of
adolescent sheep dams resulted in a significant increase in
fetal growth velocity at 3 and 4 weeks posttreatment. Despite
no significant differences in overall fetal weight, fewer fe-
tuses exhibited marked FGR in late gestation after Ad.VEGF
treatment, and there appeared to be an attenuated fetal brain
sparing effect. Ad.VEGF-transduced UtA demonstrated en-
hanced vascular reactivity and there was also upregulation of
VEGF receptors FLT1 and KDR in the maternal placental
compartment, suggesting downstream effects on placental
function. Our results support the further experimental evalu-
ation of Ad.VEGF as a potential therapy for FGR.
Acknowledgments
We would like to thank Dr. Graham Horgan (Biomathe-
matics and Statistics Scotland, Rowett Institute of Nutrition
and Health) for statistical support. Funding for the study was
received from the following sources:
 The Wellcome Trust (D.J.C.)
 Wellbeing of Women (D.J.C.)
 The Scottish Government ( J.M.W., R.P.A., J.S.M.)
 UCL/UCLH NIHR Comprehensive Biomedical Re-
search Centre (A.L.D., D.M.P.)
 The British Heart Foundation (I.C.Z.)
 Ark Therapeutics Oy, Kuopio, Finland (supplied Ad
vectors free of charge)
Author Disclosure Statement
No competing financial interests exist.
References
Barker, D.J. (2006). Adult consequences of fetal growth re-
striction. Clin. Obstet. Gynecol. 49, 270–283.
Bernstein, I.M., et al. (2000). Morbidity and mortality among
very-low-birth-weight neonates with intrauterine growth re-
striction. The Vermont Oxford Network. Am. J. Obstet. Gy-
necol. 182, 198–206.
Carr, D.J., et al. (2011). Ultrasonographic assessment of growth
and estimation of birthweight in late gestation fetal sheep.
Ultrasound Med. Biol. 37, 1588–1595.
Carr, D.J., et al. (2012). Fetoplacental biometry and umbilical
artery Doppler velocimetry in the overnourished adolescent
model of fetal growth restriction. Am. J. Obstet. Gynecol.
207, 141.e6–141.e15.
Costeloe, K., et al. (2000). The EPICure study: outcomes to
discharge from hospital for infants born at the threshold of
viability. Pediatrics 106, 659–671.
Cox, P., and Marton, T. (2009). Pathological assessment of
intrauterine growth restriction. Best Pract. Res. Clin. Obstet.
Gynaecol. 23, 751–764.
David, A.L., et al. (2008). Local delivery of VEGF adenovirus
to the uterine artery increases vasorelaxation and uterine
blood flow in the pregnant sheep. Gene. Ther. 15, 1344–1350.
Degani, S. (2001). Fetal biometry: clinical, pathological, and
technical considerations. Obstet. Gynecol. Surv. 56, 159–167.
Figueras, F., et al. (2011). Neurobehavioral outcomes in pre-
term, growth-restricted infants with and without prenatal
advanced signs of brain-sparing. Ultrasound Obstet. Gynecol.
38, 288–294.
Figueroa, R., and Maulik, D. (2006). Prenatal therapy for fetal
growth restriction. Clin. Obstet. Gynecol. 49, 308–319.
Ghidini, A. (1996). Idiopathic fetal growth restriction: a path-
ophysiologic approach. Obstet. Gynecol. Surv. 51, 376–382.
GRIT Study Group. (2003). A randomised trial of timed de-
livery for the compromised preterm fetus: short term out-
comes and Bayesian interpretation. BJOG 110, 27–32.
Halliday, H.L. (2009). Neonatal management and long-term se-
quelae. Best Pract. Res. Clin. Obstet. Gynaecol. 23, 871–880.
Holmes, D.I., and Zachary, I. (2005). The vascular endothelial
growth factor (VEGF) family: angiogenic factors in health
and disease. Genome Biol. 6, 209.
AD.VEGF GENE THERAPY FOR FGR 383
Konje, J.C., Howarth, E.S., Kaufmann, P., and Taylor, D.J.
(2003). Longitudinal quantification of uterine artery blood
volume flow changes during gestation in pregnancies compli-
cated by intrauterine growth restriction. BJOG 110, 301–305.
Lang, U., et al. (2003). Uterine blood flow—a determinant of
fetal growth. Eur. J. Obstet. Gynecol. Reprod. Biol. 110 Suppl
1, S55–S61.
Lea, R.G., et al. (2007). The expression of ovine placental
lactogen, StAR and progesterone-associated steroidogenic
enzymes in placentae of overnourished growing adolescent
ewes. Reproduction 133, 785–796.
Mandruzzato, G., et al. (2008). Intrauterine restriction (IUGR).
J. Perinat. Med. 36, 277–281.
Marlow, N., et al. (2005). Neurologic and developmental dis-
ability at six years of age after extremely preterm birth. N.
Engl. J. Med. 352, 9–19.
Mehta, V., et al. (2011). Long-term increase in uterine blood flow
is achieved by local overexpression of VEGF-A(165) in the
uterine arteries of pregnant sheep. Gene Ther. 19, 925–935.
Meschia, G. (1983). Circulation to female reproductive organs.
In Handbook of Physiology, Sect. 2, Vol. III, Part 1. J.T.
Shepherd and F.M. Abboud, eds. (American Physiological
Society, Bethesda, MD) pp 241–269.
Miller, S.L., Loose, J.M., Jenkin, G., and Wallace, E.M. (2009).
The effects of sildenafil citrate (Viagra) on uterine blood flow
and well being in the intrauterine growth-restricted fetus. Am.
J. Obstet. Gynecol. 200, 102.e1–102.e7.
Morse, S.B., et al. (2006). Racial and gender differences in the
viability of extremely low birth weight infants: a population-
based study. Pediatrics 117, e106–e112.
Nahum, G.G., and Stanislaw, H. (2003). Ultrasonographic
prediction of term birth weight: how accurate is it? Am. J.
Obstet. Gynecol. 188, 566–574.
Peebles, D.M. (2004). Fetal consequences of chronic substrate
deprivation. Semin. Fetal. Neonatal. Med. 9, 379–386.
Redmer, D.A., et al. (2005). Influence of maternal nutrition on
messenger RNA expression of placental angiogenic factors
and their receptors at midgestation in adolescent sheep. Biol.
Reprod. 72, 1004–1009.
Redmer, D.A., et al. (2009). Fetoplacental growth and vascular
development in overnourished adolescent sheep at day 50, 90
and 130 of gestation. Reproduction 137, 749–757.
Reynolds, L.P., and Redmer, D.A. (1995). Uteroplacental vas-
cular development and placental function. J. Anim. Sci. 73,
1839–1851.
Reynolds,L.P., Ferrell,C.L.,Robertson,D.A., andFord, S.P. (1986).
Metabolism of the gravid uterus, fetus and utero-placenta at sev-
eral stages of gestation in cows. J. Agric. Sci. 106, 437–444.
Robinson, J.S., Kingston, E.J., Jones, C.T., and Thorburn, G.D.
(1979). Studies on experimental growth retardation in sheep.
The effect of removal of a endometrial caruncles on fetal size
and metabolism. J. Dev. Physiol. 1, 379–398.
Roza, S.J., et al. (2008). What is spared by fetal brain-sparing?
Fetal circulatory redistribution and behavioral problems in the
general population. Am. J. Epidemiol. 168, 1145–1152.
Scherjon, S., Briet, J., Oosting, H., and Kok, J. (2000). The
discrepancy between maturation of visual-evoked potentials
and cognitive outcome at five years in very preterm infants
with and without hemodynamic signs of fetal brain-sparing.
Pediatrics 105, 385–391.
Wallace, J.M., Da Silva, P., Aitken, R.P., and Cruickshank,
M.A. (1997). Maternal endocrine status in relation to preg-
nancy outcome in rapidly growing adolescent sheep. J. En-
docrinol. 155, 359–368.
Wallace, J.M., et al. (2000). Relationship between nutritionally-
mediated placental growth restriction and fetal growth, body
composition and endocrine status during late gestation in
adolescent sheep. Placenta 21, 100–108.
Wallace, J.M., et al. (2002). Blood flows and nutrient uptakes in
growth-restricted pregnancies induced by overnourishing
adolescent sheep. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 282, R1027–R1036.
Wallace, J.M., Aitken, R.P., Milne, J.S., Hay, W.W., Jr. (2004).
Nutritionally mediated placental growth restriction in the
growing adolescent: consequences for the fetus. Biol. Reprod.
71, 1055–1062.
Wallace, J.M., et al. (2006a). Nutritional modulation of ado-
lescent pregnancy outcome—a review. Placenta 27 Suppl A,
S61–S68.
Wallace, J.M., Milne, J.S., Redmer, D.A., and Aitken, R.P.
(2006b). Effect of diet composition on pregnancy outcome in
overnourished rapidly growing adolescent sheep. Br. J. Nutr.
96, 1060–1068.
Wallace, J.M., Milne, J.S., Matsuzaki, M., and Aitken, R.P.
(2008). Serial measurement of uterine blood flow from
mid to late gestation in growth restricted pregnancies in-
duced by overnourishing adolescent sheep dams. Placenta
29, 718–724.
Zachary, I., Mathur, A., Yla-Herttuala, S., and Martin, J. (2000).
Vascular protection: a novel nonangiogenic cardiovascular
role for vascular endothelial growth factor. Arterioscler.
Thromb. Vasc. Biol. 20, 1512–1520.
Address correspondence to:
Dr. David J. Carr
Prenatal Cell and Gene Therapy Group






Received for publication December 4, 2013;
accepted after revision March 3, 2014.
Published online: March 4, 2014.
This work is licensed under a Creative Commons Attribution 3.0 United States License. You are free to
copy, distribute, transmit and adapt this work, but you must attribute this work as ‘‘Human Gene Therapy.
Copyright 2014 Mary Ann Liebert, Inc. http://liebertpub.com/hum, used under a Creative Commons Attribution
License: http://creativecommons.org/licenses/by/3.0/us/’’
384 CARR ET AL.
